This country approves Ozempic to reduce risk of kidney disease in diabetes patients

The U.S. FDA has approved Novo Nordisk’s Ozempic for reducing kidney failure risk, disease progression, and death due to heart problems in diabetes patients with chronic kidney disease. This approval marks Ozempic as the first GLP-1 treatment option for type 2 diabetes and chronic kidney disease, after showing a 24% reduction in death and major cardiac events. The U.S. FDA has approved Novo Nordisk’s Ozempic for reducing kidney failure risk, disease progression, and death due to heart problems in diabetes patients with chronic kidney disease. This approval marks Ozempic as the first GLP-1 treatment option for type 2 diabetes and chronic kidney disease, after showing a 24% reduction in death and major cardiac events.  Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle